CDNA CareDx
- 14.190
- -0.420-2.87%
- 14.500
- +0.310+2.18%
CareDx News
Craig-Hallum Maintains CareDx(CDNA.US) With Buy Rating
Craig-Hallum analyst William Bonello maintains $CareDx(CDNA.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 75.0% and a total average return of 39.3% over the past
Landmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients
Surveillance Monitoring with Both AlloSure Kidney and the AlloView AI-Enabled Risk Prediction Model Improves the Detection of All Types of Allograft Rejection AlloSure Kidney Detected Subclinical Rejection in
Express News | CareDx Inc : Jefferies Assumes Coverage With Buy Rating; Price Target $17 Vs $12
Decoding 6 Analyst Evaluations For CareDx
Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on CareDx (NASDAQ:CDNA) in the last three months.The table below summarizes their recent ratings, s
CareDx (CDNA) Gets a Hold From H.C. Wainwright
Express News | CareDx To Present New Data At The 2024 American Transplant Congress Being Held June 1-5 In Philadelphia
AI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new data to be presented at the 2024 American Transplant Congress (ATC) being held June 1-5 in Philadelphia.
Express News | CareDx Shares Are Trading Lower. The Company Announced That It Responded to Natera's Filing of a Motion for an Injunction Related to Patent 11,111,544
CareDx Responds To Natera's Filing Of A Motion For An Injunction Related To Patent 11,111,544; CareDx Informed Natera And The Court, Since August 2023, CareDx Has Utilized A New Allosure Process That It Believes Does Not Infringe On The '544 Patent.
CareDx Reiterates Position that it Does Not Infringe Natera's '544 PatentInjunction Motion has No Impact on CareDx's Business or Patient and Clinician Access to AlloSure or AlloMapCareDx, Inc. (NASDAQ
Express News | CareDx Inc - Underlying Validity of '544 Patent Also Remains Subject to Judicial Review.
Express News | CareDx Inc - Injunction Motion Has No Impact on Caredx's Business or Patient and Clinician Access to Allosure or Allomap
Express News | CareDx Reiterates Position That It Does Not Infringe the ‘544 Patent, Injunction Motion Is Irrelevant
CareDx to Participate in Upcoming Investor Conferences
CareDx, Inc. (NASDAQ:CDNA), The Transplant Company — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare
Top 3 Health Care Stocks That May Crash In May
As of May 24, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.The RSI is a momentum indicator
CareDx Is Maintained at Buy by Craig-Hallum
CareDx Is Maintained at Buy by Craig-Hallum
Analysts Offer Insights on Healthcare Companies: CareDx (CDNA), Amgen (AMGN) and Orasure Technologies (OSUR)
Express News | CareDx, Inc. : Craig-Hallum Raises Target Price to $22 From $15
Landmark Study Shows CareDx's HeartCare Outperforms Dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes With Fewer Biopsies
HeartCare Results Effectively Stratified Patients at Highest Risk for Acute Cellular Rejection Cardiologists Performed the Fewest Biopsies After Dual Negative HeartCare Results Compared to Single or Dual Positive
Express News | HC Wainwright & Co. Reiterates Neutral on CareDx
Balanced Outlook for CareDx: Strong Performance Amid Rising Competition
Analysis
Price Target
No Data
